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Summary Electrochemotherapy combines bleomycin and local electric pulses that allow cell permeabilization and free access of bleomycin
to its intracellular target. We report the first veterinarian clinical trial of electrochemotherapy in 12 cats with spontaneous large soft-tissue
sarcomas that suffered relapse after treatment with conventional therapies. Permeabilizing electric pulses were delivered using external
surface electrodes, as well as new needle-shaped electrodes that were designed to be inserted in tumours for more effective treatment of
several-centimetre-thick tumour nodules. The electric pulses were applied to the tumours several times from 4 to 15-30 min after a bolus
intravenous injection of 0.5 mg kg-1 bleomycin. Tolerance to treatment was excellent without general side-effects. The cats showed local
inflammatory reactions for a few days and disease stabilization lasted from 2 weeks to 7 months. One partial regression was observed, and
the general absence of nodule volume decrease can be explained by local fibrotic reactions. Histological analysis of biopsies also revealed
massive tumour cell death. The cats' lifespan increased (P40.001), with a mean survival time of 6.1 months (maximum 18 months) compared
with 0.8 months (maximum 1.5 months) for a group of 11 untreated control cats displaying similar carcinological features. Electro-
chemotherapy is clearly effective as a salvage treatment for large spontaneous solid tumours in adverse clinical situations and this is
promising forfuture applications.
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Bleomycin (BLM) is a non-permeant cytotoxic drug (Orlowski et
al, 1988; Poddevin et al, 1991). Appropriate brief and intense
electric pulses (EPs) transiently permeabilize cells (for review see
Chang et al, 1992 and Orlowski and Mir, 1993) in suspension (Mir
et al, 1988) as well as in tissues (Belehradek et al, 1994). Cell
electropermeabilization allows the delivery of BLM inside cells
and thus increases BLM cytoxicity by several orders ofmagnitude
(Poddevin et al, 1991; Tounekti et al, 1993). We have termed the
new anti-tumour treatment, which combines systemic BLM and
permeabilizing EPs locally delivered at the tumour site, electro-
chemotherapy (Belehradek et al, 1991, 1993; Mir et al, 1991).
Electrochemotherapy is effective in eradicating subcutaneously
transplanted small tumours (Mir et al, 1991, 1992; Serka et al,
1994; Heller et al, 1994; Yamaguchi et al, 1994). Good anti-
tumour responses were also obtained in a murine spontaneous
tumour model (Belehradek et al, 1991) and with internally trans-
planted tumours (Salford et al, 1993). In the absence ofBLM, the
applied EPs did not perturb tumour growth; conversely, in the
absence ofEPs, the doses ofBLM injected did not reduce tumour
growth whichever experimental orclinical model was tested in the
work cited above. In ulterior preclinical studies, we found that
interleukin 2 (IL-2), locally delivered in the peritumoral oedema
that appears afterelectrochemotherapy, increases the percentage of
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mice cured after one electrochemotherapy treatment (Mir et al,
1992). Moreover, we obtained systemic anti-tumour effects (Miret
al, 1995) by the combination of electrochemotherapy with local
injections of cells engineered in vitro to secrete large amounts of
IL-2 (Roth et al, 1992). Consequently, further developments
in electrochemotherapy should consider protocols in which
electrochemotherapy will be combined with immunotherapeutic
approaches.
In a phase I-II clinical trial ofelectrochemotherapy in humans,
using external electrodes, 50% of small permeation nodules of
head and neck squamous cell carcinoma went into complete
regression (Belehradek et al, 1993). Treatment was well tolerated
by the patients (Belehradek et al, 1993). Later, treatment of other
patients showed that external electrodes delivering transcutaneous
EPs were not sufficient for appropriate treatment of thick nodules
(Domenge et al, 1996). We designed a new applicator device to
deliver EPs through parallel and equidistant needles inserted into
tissues that allowedpermeabilizing EPs to reach thedeepestpart of
the nodules to be treated. The needles form a honeycomb-shaped
array for ensuring a quasi-homogeneous electric field distribution
in the tumour (Belehradek et al, 1994). Excellent local anti-tumour
efficacy on transplanted tumours in rabbit liver is currently being
obtained using this device (Ramirez et al, submitted). Before initi-
ating clinical trials in humans, it was necessary to try this new
device on large spontaneous animal tumours.
Soft-tissue sarcomas in cats (grade I or II fibrosarcomas, malig-
nant fibrohistiocytomas) appear at the interscapular area and at the
flanks (Brown et al, 1978). They always recur locally, even after
extended surgical ablation (Bostock and Dye, 1979). Adjuvant
radiotherapy can only delay the recurrence of the sarcomas, and
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Table 1 Description of the control cats
Histology and grade Last treatmentt Washoutb (months) Nodulesc Surface aread (cm2) Survivale(months)
Malignant fibrohistiocytoma Cobalt 3 1 38 1
Fibrosarcoma II Iridium 0.5 1 78 0.5
Fibrosarcoma II Cobalt 1.3 2 45 0.7
Fibrosarcoma Iridium 2.0 1 19 1.0
Fibrosarcoma II Cobalt 2.5 3 60 0.5
Malignant fibrohistiocytoma Iridium 0.5 1 50 0.5
Fibrosarcoma Iridium 4.0 1 19 1.5
Fibrosarcoma II Iridium 0.5 1 50 0.5
Malignant fibrohistiocytoma Iridium 0.5 1 50 0.7
Fibrosarcoma II Iridium 1.0 1 28 1.0
Fibrosarcoma II Cobalt 0.5 2 58 0.7
aLast treatment(s) before the electrochemotherapy; cobalt, teleradiotherapy (usually 18 Gy in six sessions of 3 Gy); iridium, curietherapy with iridium wires,
usual dose 60 Gy. bWashout period from last treatment(s). cNumber of tumour nodules. dNodules' total surface area. eCat survival after its recruitment in the
study.
Table 2 Description of the treated cats and their treatments
Histology and grade Last treatmenP Washoutb Sessionc Electrodesd ne N' Timeg Duration(h)
Cat (months) (h) (h)
1 Fibrosarcoma II Cobalt 1 1 A 8 21 4 16
2 Malignant fibrohistiocytoma Iridium 11 2-1 A 8 42 4 13
2-2 A 8 24 4 16
3 Fibrosarcoma Cobalt 2 3-1 A 8 20 8 9
3-2 B 8 20 8 9
4 Fibrosarcoma II Cobalt 1 4 C P 6 4 10
Cells 1
5 Malignant fibrohistiocytoma Cobalt 2 5-1 A 8 24 4 16
5-2 A 8 29 4 12
B 4 27
5-3 C P 8 7 17
6 Fibrosarcoma II Cobalt 6 6-1 A 8 34 5 14
6-2 A 8 40 4 17
6-3 A 8 25 31/2 10
C P 1
7 Fibrosarcoma II Iridium 4 7-1 B 8 28 4'/3 82/3
Cells 2.5 C P 1
7-2 B 8 14 4 111/2
C P 3
7-3 B 8 38 4 18
C P 7
7-4 C P 20 5 13
7-5 B 8 40 5 17
8 Fibrosarcoma II Surgery 2.5 8 A 8 23 5 15
C P 2
9 Fibrosarcoma II Cobalt 2 9 A 4 52 31/2 141/2
Cells 1 B 4 32
C P 4
10 Fibrosarcoma II Iridium 2 10 B 8 44 4 15
11 Fibrosarcoma II Cobalt 1 11-1 B 8 54 31/2 23'/2
11-1 B 8 48 4 20
12 Fibrosarcoma II Cobalt 2 12-1 C P 46 5 28
12-2 C P 35 5 24
aLast treatment(s) before electrochemotherapy; cobalt, teleradiotherapy (usually 18 Gy in six sessions of 3 Gy); iridium, curietherapy with iridium wires, usual
dose 60 Gy; cells, seven injections of 30 x 1QO xenogeneic CHO(IL-2) living cells within 8 weeks. bWashout period from last treatment(s). cElectrochemotherapy
session. dElectrodes employed as described in the text. Briefly, A are the extemal round-tip electrodes, 6 to 8 mm apart, previously used on humans, B are
external rectangular electrodes consisting of two stainless-steel plates, 6-8 mm apart, for which contact with the skin extended over 2 cm, and C are the new
needle electrodes. eNumber of EPs per run (4 or8) or programme P of device C. 'Number of EP runs delivered during the session with either the electrodes A,
B or C. gTime of the beginning of the EP delivery after the BLM bolus end. hDuration of the electrical treatment.
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Table 3 Therapeutic effects obtained
Session' Noduleb Surface area SD periodd Survival'
(cm2)' (months) (months)
1 2 31 2 7
2-(1+2) 3 27 2 10
3-(1+2) 3 51 0.3 1.5
4 3 51 0.5 2
5-(1+2+3) 11 4.3 1.5 7
6-(1+2) 3 5 6
6-(3) 2* 11 3 13
7-(1+2) 1 1.7
SCI 27 PR (7)
7-(3+4+5) 4 23 2 18
8 2 10.5 1 5
9 5 27 1 3
10 3 6
SCI 63 0 1
11-(1+2) 5 64 2 3
12-(1+2) 1 3.4
Cl 42.4 2 3
aElectrochemotherapy sessions; groups of session numbers between
brackets correspond to successive sessions performed at intervals of 2-6
weeks on the same nodules. bNumber of nodules treated; *nodules occurring
outside the previously treated area; Cl, cutaneous infiltration; SCI,
subcutaneous infiltration, as described in Materials and methods. cNodules or
Cl or SCI total surface(s). dLength of the SD (stable disease) period for which
disease did not progress after electrochemotherapy; PR, partial regression.
When recurrence after an initial SD period led to a second seres of
electrochemotherapy sessions, a second SD period is indicated. eSurvival of
the cat after the first electrochemotherapy session.
conventional chemotherapy is ineffective (Hilmas and Gilette,
1976; MacEwen et al, 1987). At the third or fourth recurrence,
surgery becomes unfeasible and usually no salvage therapy is
proposed, which limits the prognosis to a few weeks' survival. We
decided to perform an electrochemotherapy trial on soft-tissue
sarcomas in cats in this adverse situation, in spite ofa large tumour
development at the time of the cats' recruitment, which recalls
adverse situations encountered in advanced diseases in humans.
This trial using cats was designed as an actual phase I clinical trial
of a new therapeutic procedure: we recruited only cats for which
there was noproposed treatment. As wehad already shown in mice,
rats, rabbits and humans that neither BLM alone, given at 0.5-
1.0 mg kg-' (10 or 15 mg m-2 inhumans produces doses ofthe same
size) in asingle intravenous bolus, northepermeabilizing EPalone,
delivered either by surface electrodes or by needle electrodes, was
able to perturb tumour growth (Mir et al, 1991; Belehradek et al,
1993; Salford et al, 1993; Sersa et al, 1994; Ramirez et al,
submitted), the trial was focused on the comparison of completely
treated cats with untreated ones. The results reported here open the
way for initiating human clinical trials of electrochemotherapy
using the new device for intratumoral EP delivery.
MATERIALS AND METHODS
Inclusion criteria, treatment conditions and follow-up
A total of 23 cats admitted to the National Veterinary College in
Alfort, France, were entered in this study. Because of practical
constraints, it was not possible to implement rigorous randomiza-
tion in placing animals in treated and untreated groups. The cats
were in fact brought to the veterinary college for consultation
about their tumours, and inclusion in the trial depended on the
owners' acceptance of performing further treatment on their cats,
knowing that the only possibility was electrochemotherapy
proposed as part ofour trial. All cats still had good health status at
the time of their recruitment. However, they showed clinical
evidence ofdisease progression and were alreadybeyond the usual
therapeutic resources. All the tumours had recurred after surgery,
teleradiotherapy or curietherapy (Tables 1 and 2). The two groups
of cats (untreated vs treated) were similar in age [mean age of
untreated cats 10.7 ± 3.1 years (± s.d.) vs mean age oftreated cats
10.1 ± 2.5 years] surface area ofthe tumours at the time ofrecruit-
ment [45 ± 18 cm2 (Table 1) in untreated cats vs 35 ± 22 cm2
(Table 3) in treated cats] and to histological classification: two
grade I fibrosarcoma, six grade II fibrosarcoma and three malig-
nant fibrohistiocytoma in the control group (Table 1) and one
grade I fibrosarcoma, nine grade II fibrosarcoma and two malig-
nant fibrohistiocytoma in the treated group (Table 2). The cats
were brought to the clinicjust before their treatment and after the
electrochemotherapy session they were returned to their owners or
were kept for 1 day for observation. The treatment protocol was
approved by an ethics committee for animal experimentation.
The control group cats did not receive any treatment and were
simply followed up. For the treated cats, all the detectable nodules
were treated in each electrochemotherapy session. They were
anaesthetized using intravenous tiletamine and zolazepam (Zoletil,
Laboratoire Reading, Carros, France) according to the recommen-
dations of the manufacturer, with supplementary bolus, if neces-
sary, to prolong the anaesthesia. Bleomycin (Laboratoire Roger
Bellon, Neuilly-sur-Seine, France), dissolved in sterile 0.9%
sodium chloride, was injected intravenously, in a bolus that lasted
30 s, at a dose of 0.5 mg kg-'. The longest (a) and perpendicular
widest (b) dimensions of the nodules, of cutaneous infiltrations
(i.e. the large superficial tumour masses, resulting from nodule
confluence or permeation of large subcutaneous infiltrations) and
of subcutaneous infiltrations (i.e. the thin tumour masses that are
not prominent beneath the skin) were measured using callipers.
Measurements were takenbefore treatment and when cats returned
to the veterinary college. Volumes were not taken into account
because the shape of the tumours was not regular and because
only the superficial parts ofthe nodules were treated when the EPs
were delivered using the external electrodes. Thus, results of
tumourmeasurements werereported as nodule total surface, calcu-
lated from the sum of the products of the dimensions of every
distinguishable tumour mass according to the formula X x a x b/4.
Anti-tumour effects were scored according to the WHO rules:
partial regression means a decrease >50% in the size of all the
lesions.
Electrical treatments
The electrodes used were:
(A) external round-tip electrodes, 6-8 mm apart, previously used
on humans (Belehradek et al, 1993);
(B) new external rectangular electrodes consisting oftwo stain-
less-steel plates, 6-8 mm apart, for which contact with skin
extended over 2 cm (thus, skin or tumour total surface
covered by B was larger than that covered by A);




Figure 1 Histological examination of a biopsy of a treated nodule
performed 1 month after electrochemotherapy. Paraffin-embedded tumour
sections were stained with haemalun-eosin. (A) Picture at low magnification
(scale bar = 200,im) showing massive necrosis and a large inflammatory
reaction around and inside the tumour. (B) Picture at intermediate
magnification (scale bar = 50gm) showing the presence of macrophages,
lymphocytes and eosinophils at the periphery of the treated nodule.
(C) Picture at high magnification (scale bar = 20gim) of the previous field
showing the presence of tumour cells with very large nuclei
(C) intratumoral electrodes consisting ofseven parallel equidis-
tant needles, 1.5 cm long, 6 mm apart, arranged as a centred
'honeycomb', fixed by an insulating template and inserted in
the tumour for EP delivery.
For both the A and B external electrodes, electrical contact with
the shaved skin was ensured by means of electrocardiography
paste. Series of 100-gs EPs with 1300 V cm-' electric field inten-
sity (ratio of the applied voltage to the distance between the elec-
trodes) were delivered at a frequency of 1 Hz by a Jouan PS15
electropulsator (Nantes, France) and checked using a digital
storage oscilloscope (Hitachi, Tokyo, Japan).
For the C 'internal' electrodes, the EPs were delivered by a
CELTEM MKO generator (Antony, France) at a frequency of 4
or 6 Hz and were distributed successively to each pair of closest
electrodes by an integrated switch to give eight pulses (four of
each polarity) of 100 ,us and 800 V cm-' between each pair of
needles, at a final frequency ofrespectively, 0.33 or 0.5 Hz. With
the seven needle centred 'honeycomb' applicator, there are 12
pairs of equidistant closest electrodes. The duration of an entire
run according to this programme, designated P (see column 'n' in
Table 2) was 24 or 16 s.
As a general rule, small nodules and infiltrations with a reduced
thickness, as revealed by palpation, were treated with the surface
electrodes, whereas thick nodules and thick infiltrations were
treated with the needle electrodes.
Associated immunotherapy
Electrochemotherapy was usually performed 1 day later by peri-
or intratumoral injection of30 x 106xenogeneic CHO(IL-2) living
cells, cultured in vitro under the usual culture conditions,
trypsinized for a few minutes before their administration and
resuspended in 3 ml of culture medium without fetal calf serum.
The treated cats received seven injections during a period of 8
weeks. CHO(IL-2) cells are ovarian cells from Chinese hamster
transfected with the human gene coding for IL-2 and in vitro
secreting 3500 units of IL-2 per ml, 72 h and 0.8 x 105 initially
seeded cells (Ferrara et al, 1987).
RESULTS
Treatment procedures using externally delivered
electric pulses
For the 12 cats ofthe treated group, BLM at a dose of0.5 mg kg-'
was injected intravenously in a bolus that lasted 30 s. This dose,
similar on abody weight basis to that used in otherpreclinical and
clinical trials (Belehradek et al, 1993; Salford et al, 1993; Heller et
al, 1994; Sersa et al, 1994; Yamaguchi et al, 1994), is totally inef-
fective in the absence of the potentializing EP. The nodules ofthe
first cats and the thin nodules of other cats were treated using the
procedure previously tested in other animal species as well as in
humans (Belehradek et al, 1991, 1993; Mir et al, 1991, 1992), i.e.
using transcutaneous EPs with external electrodes. Thus, 100js
and 1300 V cm-' EPs were delivered at 1 Hz, in runs of four or
eight pulses, through two external stainless-steel electrodes (A or
B) placed over the treated nodule (Table 2). In the absence of
BLM, these EPs are totally ineffective (Belehradek et al, 1993;
Heller et al, 1994; Sersa et al, 1994; Yamaguchi et al, 1994). In the
electrochemotherapy sessions, all the EPs were delivered in less
than 25 min, starting roughly 4 min after BLM administration. For
the treatment ofsmall nodules, electrodes were placed at each side
of the nodule and one run of four or eight EPs delivered. For the
treatment of extended thin nodules, the electrodes were placed
successively at adjacent positions to cover all the surface of the
nodule, and each position was treated by one EP run.
The new device for treatments using intratumorally
delivered electric pulses
The new device consists ofa support for seven parallel equidistant
needles (1.5 cm long) arranged as a centred 'honeycomb', i.e. as a
centred hexagonal array geometry. This geometry defines 12 pairs
ofclosest electrodes (needles), all separated by the same distance,
6 mm, and thus the tumour is divided into 12 volume units treated
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separately with rather low voltages [at 800 V cm-' (see below) and
with 6 mm between the needles, the voltage delivered is only
480 V] (this concept has been patented by the CNRS). These elec-
trodes allow treatment of the deepest parts of the tumours even in
the thickest nodules. Indeed, with the implanted needles, the elec-
tric field will be delivered at the same depth as the electrodes. It is
noteworthy that the electric field distribution is easily controlled
by the voltage generator and is not subjected to dissipation
phenomena as long as the potential difference is maintained
between the electrodes.
The geometry ofthe electric field distribution across the tumour
and the neighbouring tissues is obviously different whether
internal or external electrodes are used. Thus, for intratumoral EPs
with the new device we chose to apply 800 V cm-1 as our previous
ex vivo studies (Belehradek et al, 1994) showed that 500-
600 V cm-1 was the minimal electric field intensity necessary to
obtain cell permeabilization with electrodes directly in contact
with tissues. Moreover, 800 V cm-' was the electric field intensity
previously delivered using only two needles for the treatment of
gliomas transplanted intracranially in rats (Salford et al, 1993).
These EPs do not affect tumour cell viability in the absence of
BLM (Belehradek et al, 1994). To ensure the treatment of the
whole tumour, the needle applicator was successively repositioned
in adjacent positions in the tumour after each run to cover the
whole tumour volume.
Electrochemotherapy effects
Tolerance to electrochemotherapy was excellent. No bleeding after
the needles were inserted and no burns were observed. Repetition
of the treatment (up to five sessions, Table 2) did not induce any
negative general effect and did not impair the cats' health status.
After electrochemotherapy, they ate and behaved as usual and did
not show any sign ofpain. In the days after electrochemotherapy,
only local reactions were observed. Tumoral and peritumoral
electropulsed regions displayed an intense inflammatory reaction,
with an oedema detectable up to 1 week. After treatment using the
needle applicator, localhyperthermia, easily detectedbypalpation,
was sometimes associated with an inflammatory reaction in the
absence ofsystemic fever.
As tumours were embedded in oedema during the first days
after electrochemotherapy, total apparent diameters were larger
than those initially recorded. After the disappearance of oedema,
measurements ofthe largest tumour masses were often identical to
those taken before electrochemotherapy. However, tumour growth
was stopped for a period between 2 weeks and 7 months, even in
the cases in which tumour growth was very rapid before electro-
chemotherapy (Table 3). The smallest nodules (diameter <1 cm),
frequently disappeared completely. However, because of the
simultaneous presence of large nodules in cats suffering advanced
disease, we could never score a complete regression ofthe malig-
nancy. Global response could not be consideredbetter than disease
stabilization except, in one case, a partial regression (decrease in
the size ofall the nodules by at least 50%) that lasted for 7 months
(Table 3). The most relevant benefit was obtaining large increases
in survival times: up to 7, 10, 13 and 18 months [mean survival
time 6.1 ± 5.2 (± sd) months; median survival time 5.0 months].
This increase in lifespan was obtained without loss of the cats'
quality oflife. The comparison with the spontaneous survival time
of the cats in the control group [mean survival time 0.8 ± 0.3
months (Table 1), with a maximal survival time of 1.5 months and
a median survival time of 0.7 months] shows that the increase in
lifespan of the treated cats is highly significant (F= 204 in the
Fisher-Snedecor test; P << 0.001).
Histological observations
Three biopsies were performed, 1 month (one sample) and 2
months (two samples) after electrochemotherapy. The tumour
tissue was modified with a large detectable inflammatory reaction
around and inside the treated tissue (Figure IA). Macrophages and
lymphocytes were present in large numbers, as well as a specific
eosinophil infiltration (Figure lB and C). These observations are
in agreement with other histological studies in rabbits (Ramirez et
al, submitted). Even ifsome remnants ofviable tumour tissue were
still detectable, most ofthe tumour cells were enlarged and showed
pyknosis and cytoplasmic vacuolization, indicative of massive
necrosis. These observations demonstrate that, in spite of a weak
effect on the apparent size of the palpable nodules, tumour tissues
treated by electrochemotherapy were massively necrosed. This can
help to understand the discrepancy between the low rate of objec-
tive responses (only one partial regression) and the large increases
in the survival times.
DISCUSSION
The basis of electrochemotherapy is the cell permeabilization by
the EPs delivered to the tumours, to allow BLM, or other non-
permeant cytotoxic drugs, to enter the cells in large amounts and to
reach their intracellular targets. Electrochemotherapy development
objectives are (i) to design devices that allow the adequate delivery
of permeabilizing EPs to the entire tumour to be treated, even
if nodules are large and/or deep, (ii) to show that electro-
chemotherapy is feasible and is locally efficient even in situations
in which conventional anti-tumour therapies are not useful and (iii)
to extend the electrochemotherapy local effectiveness to systemic
anti-tumour effects. We report here the results of the efficacy of
electrochemotherapy in an animal clinical situation that is particu-
larly interesting as the treated tumours (i) recur very rapidly after
conventional treatments and (ii) have sizes comparable with those
encountered in humans.
As in all the previously examined preclinical and clinical situa-
tions, tolerance to the electrochemotherapy was excellent, both
during and after the EP delivery (Mir et al, 1991, Belehradek et al,
1993; Salford et al, 1993; Domenge et al, 1996). No side-effects
because of the BLM, the EPs or the IL-2-secreting cell injections
were noticed. In particular, the intratumoral delivery of a large
number of EPs with inserted needle electrodes did not produce
adverse reactions. Thus, it is feasible and safe to perform electro-
chemotherapy using the principle on which the design of the
needle-electrode applicator is based, i.e. the principle of dividing
large tumours into separate volume elements that are treated indi-
vidually by a large numberofmoderate voltage EPs. Indeed, in this
case treatment is much saferthan thatin which EPs are delivered to
large tumours using only two external electrodes that are placed at
each edge of the tumour nodules and which obviously require
much higher voltages because of the much large interelectrode
distance. Therefore, needle electrodes now appear to be appro-
priate forthe treatment oflarge tumours. It is difficult to determine
if surface or needle electrodes have different efficiencies. Indeed,
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as stated in Materials and methods, they are used in different situa-
tions according to tumour thickness and, for example, some cats
were treated using both electrodes depending on the thickness of
different parts oftheir sarcomas (Table 2).
The cytotoxic effects ofthe electrochemotherapy on the tumour
cells were characterized by a very large increase in cell and nuclei
size. This observation is in agreement with our in vitro findings
concerning cell death inducedby BLM. We have shownthat, when
relatively low amounts ofBLM molecules enterthe cells (between
a few hundreds and several tenths of thousands molecules per
cell), cells die through a slow process reminiscent of the mitotic
cell death described in the case ofionizing radiations (Tounekti et
al, 1993). This could explain why, 1 month after the treatment,
some tumour cells seem to be alive even ifthey are highly modi-
fied and definitely condemned to death. This slow process of cell
death could be of interest in sustaining the immunological anti-
tumour responses and, being concomitant with the appearance of
the fibrotic reaction detected in biopsies, can explain why the
apparent volume ofthe tumour tissue did not decrease and, conse-
quently, why we did not score complete regressions even if elec-
trochemotherapy regularly allowed achievementoflongperiods of
stable disease and longer survival times than in the untreated cats.
A previous trial concerning the tolerance ofhealthy cats to the
injections of living xenogeneic CHO(IL-2) cells had shown that
these cells were well tolerated, without reactions even after eight
ortenconsecutive injections within 2 months (PDevauchelle et al,
unpublished results). Here also, in cats displaying large tumour
masses treated by electrochemotherapy, local injections of these
cells at the tumour site have been well tolerated, suggesting that
they may be safely tested in future clinical trials in humans. This
seems important as we obtained systemic anti-tumour effects in
mice when we combined electrochemotherapy with immuno-
therapy based on the injections of histoincompatible IL-2-
secreting cells (Mir et al, 1995). Ulterior phase II trials will be
useful to determine the contributions of electrochemotherapy and
IL-2-secreting cells on the anti-tumour effects observed, even if
we already presume that this adjuvant or a related immunotherapy
would be included in future trials.
In summary, this study describes the first application of
electrochemotherapy to cats' spontaneous soft-tissue sarcomas,
considered as a clinical model for the treatment of large solid
tumours resistant to conventional anti-tumour treatments. The
results demonstrate the possibility of initiating safe phase II trials
on less advanced soft-tissue sarcomas or on other malignancies
developing cutaneously or subcutaneously in domestic carnivores.
It also illustrates electrochemotherapy feasibility on large and
thick nodules using intratumoral EPs delivered by a new device
used for the first time in this trial. Tolerance to the treatment was
excellent and we obtained a clear increase in the lifespan of the
treated cats in comparison with the control untreated cats. These
facts are of importance in prompting the beginning of similar
clinical trials in humans.
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